Method for predicting response to HDACi / DNMTi combination in multiple myeloma

摘要

The present invention relates to whether patients suffering from multiple myeloma respond to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) and at least one DNA methyltransferase inhibitor (DNMTi). A method of testing comprising: i) determining expression levels (ELi) of several genes G1-Gn selected from Table A in a biological sample obtained from said patient; and ii) step a step of comparing the expression level (ELi) determined in i) with a predetermined reference level (ELRi), and iii) the following formula (I) (where βi represents a regression β coefficient reference value of the gene Gi) When the expression (ELi) of the gene Gi is higher than the predetermined reference level (ELRi), Ci = 1, or the expression (ELi) of the gene is lower than the predetermined reference level (ELRi). And if ii) Ci = -1), the step of calculating the HAADMS score through iv) the step of comparing the score HADMS determined in step iii) with a predetermined reference value HADMSR; Concludes that the patient responds to the combination treatment when higher than a predetermined reference value HADMSR, or concludes that the patient does not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMSR And the attaching process.